|
|
Clinical study of Houpo Paiqi Mixture in the treatment of patients with sepsis acute gastrointestinal injury#br# |
LI Wei YU Xingqun GAO Zhiling NIE Weiqun WANG Longmei |
Department of Critical Care Medicine, the First Affiliated Hospital of Anhui University of Chinese Medicine, Anhui Province, Hefei 230031, China |
|
|
Abstract Objective To explore the clinical effect of Houpo Paiqi Mixture in the treatment of patients with sepsis acute gastrointestinal injury. Methods A total of 40 patients with sepsis acute gastrointestinal injury hospitalized in the Department of Critical Care Medicine of the First Affiliated Hospital of Anhui University of Chinese Medicine from April 2020 to May 2021 were selected as the research objects. They were divided into control group and intervention group according to random number table method, with 20 cases in each group, the control group was treated with conventional Western medicine, the intervention group was treated with Houpo Paiqi Mixture on the basis of the control group, 7 days for a course of treatment. The changes of procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP), the number of bowel sounds, enteral nutrition, sequential organ failure assessment score (SOFA), acute physiology and chronic health score Ⅱ (APACHE Ⅱ), and clinical effects were observed in the two groups. Results After treatment, hS-CRP and PCT in the two groups were lower than those before treatment, and the intervention group was lower than those in the control group (P < 0.05). After treatment, the frequency of bowel sounds and enteral nutrition in the two groups were higher than those before treatment, and the intervention group was higher than those in the control group (P < 0.05). After treatment, SOFA score and APACHE Ⅱ score of the two groups were lower than those before treatment, and the intervention group was lower than those in the control group (P < 0.05). The clinical effect of intervention group was better than that in the control group (P < 0.05). Conclusion Houpo Paiqi Mixture for patients with sepsis acute gastrointestinal injury is better than simple treatment of Western medicine, can reduce inflammatory reaction, improve gastrointestinal function, reduce the degree of critical illness, also improve the prognosis.
|
|
|
|
|
[1] Xie J,Wang H,Kang Y,et al. The Epidemiology of Sepsis in Chinese ICUs:A National Cross-Sectional Survey [J]. Crit Care Med,2020,48(3):e209-e218.
[2] Liu V,Escobar GJ,Greene JD,et al. Hospital deaths in patients with sepsis from 2 independent cohorts [J]. JAMA,2014,312(1):90-92.
[3] Mervyn S,Clifford S Deutschman,Christopher Warren Seymour,et al. The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J]. JAMA,2016, 315(8):801-810.
[4] Reintam BA,Malbrain ML,Tarkopf J,et al. Gastrointestinal function in intensive care patients:terminology,definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems [J]. Intensive Care Med,2012,38(3):384-394.
[5] 中华中医药学会中医诊断学分会.中医常见证诊断标准(上)[J].湖南中医药大学学报,2008,28(5):3-8.
[6] 中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:361-364.
[7] Zhang D,Li Y,Ding L,et al. Prevalence and outcome of acute gastrointestinal injury in critically ill patients:A systematic review and meta-analysis [J]. Medicine(Baltimore),2018,97(43):e12970.
[8] Bastiaan WH,Wiersinga WJ. The role of the gut microbiota in Sepsis [J]. Lancet Gastroenterol Hepatol,2017,2(2):135-143.
[9] Xing X,Zhi Y,Lu J,et al. Traditional Chinese medicine bundle therapy for septic acute gastrointestinal injury:A multicenter randomized controlled trial [J]. Complementary Therapies in Medicine,2019,47(39):102194.
[10] Xue ZZ,Wu CX,Wei JY,et al. An orally administered magnoloside A ameliorates functional dyspepsia by odulating brain-gut peptides and gut microbiota [J]. Life Sci,2019,233(15):116749.
[11] 谭珍媛,邓家刚,张彤,等.中药厚朴现代药理研究进展[J].中国实验方剂学杂志,2020,26(22):228-234.
[12] Wu F,Yao HP,Zheng FP,et al. Protective effects of honokiol against oxidative stress induced apoptotic signaling in mouse podocytes treated with H202 [J]. Exp Ther Med,2018,16(2):1278-1284.
[13] 周雯,万建国,邬叔兵,等.大黄治疗脓毒症急性胃肠损伤的临床研究[J].江西医药,2021,56(2):156-158.
[14] 林呼,黄喜文,黄清苑,等.健脾和胃方对缓解化疗后胃肠道反应症状的临床观察[J].中国医药科学,2020,10(19):94-96.
[15] 师拥周.中西医联合治疗术后胃肠功能障碍的临床研究[J].数理医药学杂志,2020,33(5):756-757.
[16] 任珊,宫蕊,龙玲,等.厚朴排气合剂对肺炎合并急性胃肠功能损伤患者 预后的影响研究[J].现代中西医结合杂志,2020,29(18):1973-1976.
[17] 李桥辉,蓝雪容,黄轶喆,等.厚朴排气合剂对剖宫产术后肠道功能恢复效果的影响及安全性[J].白求恩医学杂志,2019,17(1):84-86.
[18] 严伟恒,靳媛媛,王宽,等.烧伤早期伴发脓毒症患者血清PCT、hs-CRP、COR及WBC的动态变化及临床意义[J].现代生物医学进展,2020,20(4):760-763.
[19] 赵倩,谢月群,张涛,等.降钙素原对脓毒症患者病情及预后的临床价值[J].中华急诊医学杂志,2016,25(7):937-943.
[20] 中国医药教育协会感染疾病专业委员会.降钙素原指导抗菌药物临床合理应用专家共识[J].中华医学杂志,2020,100(36):2813-2821.
[21] 陈静波.C反应蛋白、降钙素原对脓毒症患者早期诊断及病情评估的应用价值[J].国际检验医学杂志,2020, 41(2):242-244.
[22] 孙仁华,江荣林,黄曼,等.重症患者早期肠内营养临床实践专家共识[J].中华危重病急救医学杂志,2018,30(8):715-721.
[23] 魏清兰,钟建,冯艳,等.自拟健脾调肠方加减对脓毒症患者肠内营养耐受性及免疫指标的影响[J].中国中医急症,2021,30(2):271-273,281.
[24] 于凯江,杜斌.重症医学[M].北京:人民卫生出版社,2015.
[25] 张慈,张盼盼,余华丽,等.血浆sTREM-1水平及SOFA对老年脓毒症患者病情及预后的评估价值[J].中国老年学杂志,2020,39(14):3443-3445. |
|
|
|